Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Editorial

Angiotensin II Type 1 Receptor–associated Protein

A Novel Modulator of Angiotensin II Actions in the Nephron

Jorge F. Giani, Sebastien Fuchs, Romer A. Gonzalez-Villalobos
Download PDF
https://doi.org/10.1161/HYPERTENSIONAHA.113.01150
Hypertension. 2013;61:1150-1152
Originally published May 15, 2013
Jorge F. Giani
From the Departments of Biomedical Sciences and Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastien Fuchs
From the Departments of Biomedical Sciences and Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Romer A. Gonzalez-Villalobos
From the Departments of Biomedical Sciences and Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Introduction
    • Acknowledgements
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Introduction

See related article, pp 1203–1210

Most physiological actions of angiotensin (Ang) II are mediated by its binding to the Ang II type 1 receptors (AT1R). These include, but are not limited to, vasoconstriction, increased renal sodium and water reabsorption, as well as the stimulation of aldosterone release, thirst, vasopressin secretion, and cell growth. Not surprisingly, the biochemistry of the AT1R has been a subject of intense research for >30 years. These studies revealed that the cytoplasmic tail of the AT1R is an important site for several protein-to-protein interactions, phosphorylation, and thereby the regulation of receptor signaling, desensitization, and endocytosis.1 Accordingly, considerable efforts have been made to identify and to study molecules with affinity to this region; one of such molecules is the angiotensin receptor–associated protein (ATRAP).

ATRAP is an 18-kDa protein that was first identified and cloned in 1999 using a yeast 2-hybrid assay.2 Successive in vitro studies showed that ATRAP lacks catalytic activity.3 Instead, ATRAP is a membrane protein with 3 predicted transmembrane domains and a cytoplasmic tail that is important for its interactions with the carboxyl terminal of the AT1R.3 ATRAP colocalizes with the AT1R mostly in intracellular compartments, it induces AT1R internalization and reduces its signaling.2,3 Thus, available data indicate that ATRAP is a negative modulator of AT1R activity. ATRAP is made by many organs, including the heart, testis, and adrenal glands. However, by far the kidneys are the site of highest expression.2

Studies using gene targeting technology have provided valuable insights into the physiological role of ATRAP. For instance, the systemic knockdown of ATRAP elevates blood pressure by ≈8 mm Hg.4 Although vascular reactivity to Ang II was preserved, it was observed that ATRAP knockout mice have elevated plasma and blood volume. These results indicated that ATRAP absence increased sodium and water retention by the kidneys. Accordingly, Ang II binding to the renal cortex, a surrogate for AT1R surface abundance, was increased in the mutant mice. This was accompanied by increased carbonic anhydrase responsiveness, a measure of proximal tubule function. Hence, it was concluded that ATRAP was a blood pressure modulator because of its negative effects on proximal tubular AT1R function and, consequently, sodium and water balance.

In this issue of Hypertension, Wakui et al5 analyzed the responses to Ang II infusion of transgenic mice overexpressing ATRAP predominantly in the distal nephron. Detailed analysis of renal ATRAP expression in their mutant strain revealed that distal regions of the nephron, from the distal to connecting tubules, were the sites of highest expression for the transgenic protein. The most important observation by Wakui et al5 is that ATRAP overexpression in the distal nephron blunted the pressor response to Ang II. In their experiments, the basal systolic blood pressure of the transgenic mice and wild-type mice was similar. However, during Ang II infusion, the blood pressure increase was 20 mm Hg lower in the mutant mice when compared with equally treated wild-type controls. This is no small feat considering that AT1Rs in extrarenal tissues were presumably not affected by the genetic manipulation.

To investigate the consequences of ATRAP overexpression on renal function during Ang II infusion, the authors performed balance studies and explored the expression of several key sodium transporters along the nephron. Specifically, they measured the abundance of the proximal tubule Na+/H+ exchanger 3, the loop of Henle Na+/K+/2Cl− cotransporter 2, the distal tubule NaCl cotransporter, and the epithelial sodium channel. Their balance studies indicated that the transgenic mice responded to Ang II infusion with less sodium and water retention. Importantly, the enhanced natriuresis of the mutant mice was associated with a failure to increase NaCl cotransporter phosphorylation and the α subunit of epithelial sodium channel, indirect indicators of transport activity. Thus, the segmental ATRAP overexpression was associated with suppression of corresponding transporters and the consequent enhanced natriuresis. Accordingly, the authors concluded ATRAP protects against the Ang II–induced hypertension because it prevents the induction of sodium transport in distal segments of the nephron. These observations are novel because, although it is known that Ang II induces the activity and expression of NaCl cotransporter and epithelial sodium channel,6,7 it was not known that ATRAP can modulate such an effect (Figure).

Figure.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure.

Hypothetical model for angiotensin receptor–associated protein (ATRAP) negative modulation of angiotensin II effects to increase sodium reabsorption in the distal nephron. In wild-type mice (top), angiotensin (Ang) II binding to Ang II type 1 receptors (AT1R) expressed in the distal tubule (DT) and connecting tubules (CNT) induces the activity of the NaCl cotransporter (NCC) and the epithelial sodium channel (ENaC). In transgenic mice (bottom), ATRAP increased abundance, reduces AT1R surface expression in DT and CNT, and consequently, Ang II binding and its induction of sodium transport.

The study by Wakui et al5 contains several conundrums. First, there is a discrepancy with previous reports as to where ATRAP is expressed within the kidneys. Although Oppermann et al4 reported that ATRAP is mostly expressed in the proximal tubule, the studies from Umemura’s group suggest a more extensive distribution.5,8 According to these authors, endogenous ATRAP is expressed in glomeruli, vasculature, proximal, and distal segments of the nephron. Moreover, in their analyses, the distal nephron is the site of highest expression. The reason for such difference is unknown, and it should be a topic for future investigation. The second issue deals with the lack of an ATRAP effect on baseline blood pressure of the transgenic mice. The authors suggest that ATRAP is only important in pathological conditions, but a mechanistic explanation for this is missing. The third issue is that the impact of overexpressing ATRAP on the actual activity of NaCl cotransporter or epithelial sodium channel (ie, in vivo response to specific blockers) was not evaluated. Fourth, if the transgene is overexpressed predominantly in the distal nephron, it follows that it is probably under the control of a region-specific enhancer. Hence, it is possible that the transgene insertion disrupted the corresponding locus and its physiological role. Finally and most importantly, the fact that a very high ATRAP expression (33-fold mRNA increase in distal tubules and 10-fold protein increases in total kidney homogenates) was necessary to reduce the response to Ang II suggests that ATRAP effects may be minor.

Regardless of the previous observations, the study by Wakui et al5 emphasizes the tremendous impact of the kidneys in the hypertensive response to Ang II, while highlighting the potential of ATRAP as a negative modulator. The authors present interesting evidence for the tuning down effect of ATRAP on Ang II actions to increase sodium avidity in the nephron. These results add to the mounting evidence in favor of an important role of AT1Rs expressed in various segments of the nephron in long-term blood pressure regulation.9,10 The presented evidence and future details on how ATRAP affects AT1R signaling may lead to a more comprehensive understanding of Ang II actions to regulate renal function. Finally, the possible effect of ATRAP on other renal processes is also intriguing. For instance, it is increasingly recognized that inappropriate activation of the intrarenal RAS is an important cause of hypertension.10 However, the effects of ATRAP on the local pool of Ang II are unknown.

Only time will tell whether there is any usefulness in the pharmacological manipulation of ATRAP expression. Ultimately, the recent discovery of ATRAP and the ongoing elucidation of its effects remind us that we should not assume to possess the complete picture of Ang II actions in renal physiology and hypertension.

Acknowledgements

We thank Brian Taylor for helping us in the preparation of this manuscript.

Sources of Funding

We received support from the National Institute of Diabetes and Digestive and Kidney Diseases (R00DK083455).

Disclosures

None.

Footnotes

  • The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

  • © 2013 American Heart Association, Inc.

References

  1. 1.↵
    1. Hunyady L,
    2. Catt KJ
    . Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 2006;20:953–970.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Daviet L,
    2. Lehtonen JY,
    3. Tamura K,
    4. Griese DP,
    5. Horiuchi M,
    6. Dzau VJ
    . Cloning and characterization of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor. J Biol Chem. 1999;274:17058–17062.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Lopez-Ilasaca M,
    2. Liu X,
    3. Tamura K,
    4. Dzau VJ
    . The angiotensin II type I receptor-associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II signaling. Mol Biol Cell. 2003;14:5038–5050.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Oppermann M,
    2. Gess B,
    3. Schweda F,
    4. Castrop H
    . Atrap deficiency increases arterial blood pressure and plasma volume. J Am Soc Nephrol. 2010;21:468–477.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Wakui H,
    2. Tamura K,
    3. Masuda S-i,
    4. Tsurumi-Ikeya Y,
    5. Fujita M,
    6. Maeda A,
    7. Ohsawa M,
    8. Azushima K,
    9. Uneda K,
    10. Matsuda M,
    11. Kitamura K,
    12. Uchida S,
    13. Toya Y,
    14. Kobori H,
    15. Nagahama K,
    16. Yamashita A,
    17. Umemura S
    . Enhanced angiotensin receptor-associated protein in renal tubule supresses angiotensin-dependent hypertension. Hypertension. 2013.;61:1203–1210.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. van der Lubbe N,
    2. Lim CH,
    3. Fenton RA,
    4. Meima ME,
    5. Jan Danser AH,
    6. Zietse R,
    7. Hoorn EJ
    . Angiotensin II induces phosphorylation of the thiazide-sensitive sodium chloride cotransporter independent of aldosterone. Kidney Int. 2011;79:66–76.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Komlosi P,
    2. Fuson AL,
    3. Fintha A,
    4. Peti-Peterdi J,
    5. Rosivall L,
    6. Warnock DG,
    7. Bell PD
    . Angiotensin I conversion to angiotensin II stimulates cortical collecting duct sodium transport. Hypertension. 2003;42:195–199.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Tsurumi Y,
    2. Tamura K,
    3. Tanaka Y,
    4. Koide Y,
    5. Sakai M,
    6. Yabana M,
    7. Noda Y,
    8. Hashimoto T,
    9. Kihara M,
    10. Hirawa N,
    11. Toya Y,
    12. Kiuchi Y,
    13. Iwai M,
    14. Horiuchi M,
    15. Umemura S
    . Interacting molecule of AT1 receptor, ATRAP, is colocalized with AT1 receptor in the mouse renal tubules. Kidney Int. 2006;69:488–494.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Gurley SB,
    2. Riquier-Brison AD,
    3. Schnermann J,
    4. Sparks MA,
    5. Allen AM,
    6. Haase VH,
    7. Snouwaert JN,
    8. Le TH,
    9. McDonough AA,
    10. Koller BH,
    11. Coffman TM
    . AT1A angiotensin receptors in the renal proximal tubule regulate blood pressure. Cell Metab. 2011;13:469–475.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Navar LG,
    2. Kobori H,
    3. Prieto MC,
    4. Gonzalez-Villalobos RA
    . Intratubular renin-angiotensin system in hypertension. Hypertension. 2011;57:355–362.
    OpenUrlFREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
June 2013, Volume 61, Issue 6
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Introduction
    • Acknowledgements
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Angiotensin II Type 1 Receptor–associated Protein
    Jorge F. Giani, Sebastien Fuchs and Romer A. Gonzalez-Villalobos
    Hypertension. 2013;61:1150-1152, originally published May 15, 2013
    https://doi.org/10.1161/HYPERTENSIONAHA.113.01150

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Angiotensin II Type 1 Receptor–associated Protein
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Angiotensin II Type 1 Receptor–associated Protein
    Jorge F. Giani, Sebastien Fuchs and Romer A. Gonzalez-Villalobos
    Hypertension. 2013;61:1150-1152, originally published May 15, 2013
    https://doi.org/10.1161/HYPERTENSIONAHA.113.01150
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Cardiology
    • Etiology
      • Hypertension
        • Hypertension
  • Basic, Translational, and Clinical Research
    • Ion Channels/Membrane Transport
    • ACE/Angiotensin Receptors/Renin Angiotensin System

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured